GENERIC DRUG IN GLOBAL MARKET AND REGULATORY ENVIRONMENT by Pankaj Kumar*, Bharti Mangla2, Satbir Singh, Arapna Rana
IAJPS 2017, 4 (12), 4705-4719                    Pankaj Kumar et al                        ISSN 2349-7750 
 
 
w w w . i a j p s . c o m  
 
Page 4705 
 
    CODEN [USA]: IAJPBB                          ISSN: 2349-7750 
 
  INDO AMERICAN JOURNAL OF 
  PHARMACEUTICAL SCIENCES 
 
            
 
 
Available online at: http://www.iajps.com                                      Research Article 
 
GENERIC DRUG IN GLOBAL MARKET AND REGULATORY  
ENVIRONMENT 
Pankaj Kumar1*, Bharti Mangla2, Satbir Singh1, Arapna Rana1 
1Department of Pharmaceutics, Advanced Institute of Pharmacy, Palwal, Haryana, India-121102 
2Department of Pharmaceutics, Jamia Hamdard University, New Delhi, India 11062 
Abstract: 
Different regulatory authorities regulate the drug development in various countries of the world. Various 
Regulatory authority for generic drug application Food and Drug Administration (FDA), European Medicines 
Agency (EMA), Pharmaceutical and Medical Devices Agency (PMDA), Health Product and Food Branch (HPFB) 
Central Drug Standard of Organization (CDSO).  Generic manufacturers may file an abbreviated New Drug 
Application (ANDA) that incorporates the safety/effectiveness data submitted by original innovator drug 
manufacturer and adds only bioequivalence studies. Therefore it is very difficult and challenging task to approve a 
drug by the manufacturing companies, simultaneously submitted in all the regulatory authorities. Regulatory 
authorities are responsible to ensure the quality, safety, and efficacy including manufacturing, distribution of the 
drug product. There is lot of challenges for the pharmaceutical industry to development and filling of generic drug 
application, which can be overcoming by the common format of submission. This is due to the different 
regulatory procedure of the various countries.  Through the international conference on harmonization (ICH) 
process common technical documents (CTD) has been developed for USA, EU, JAPAN, INDIA AND CANADA. 
There are few differences in the dossier submission for among these five regions. To development of any generic 
drug product still we need strategic planning by these regulatory authorities. 
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INTRODUCTION: 
Generic drugs are marketed after the expiries of the 
patent or marketing right of the patented drug are 
available at the affordable price. The generic drugs 
are approved by the respective controlling authority 
of the country as innovative drugs with regard to 
efficacy, bioavailability etc.[1]Generic drugs may 
differ in shape, scoring configuration, release 
mechanisms, packaging, excipients (colors, flavors, 
preservatives), and product expiration. If drugs with 
such differences are substituted for each other, there 
is a potential for patient confusion. The main 
difference between generic and brand-name drugs is 
the amount and type of evidence supporting the 
market application of the respective drug. A brand-
name drug is required to demonstrate substantial 
preclinical and clinical evidence showing safety and 
efficacy in a patient population. [3] After the expiry 
of patent or marketing rights of the patented drug, 
generic drugs are marketed. Generic drugs are 
available at affordable prices with maintaining 
quality.[3]The drug price competition and patent term 
restoration act of 1984, commonly known as hatch 
Waxman act allowed ANDA to be possible by 
making a comprise in drug companies. The hatch 
Waxman act of 1984 paved the way for the generic 
drug to enter to the market.[4] with the increasing in 
pressure of healthcare costs all the large innovator 
companies as well as Indian MNCs drive up their 
business in generic market.[5]The pharmaceutical 
industry, while pursuing an international market, is 
obliged to comply with national regulations. The 
pharmaceutical industry is now perhaps the most 
highly regulated of all industries demanding a high 
level of information to be submitted to governments 
before a pharmaceutical product is brought to the 
market place. Regulatory authorities can be said to be 
the function responsible for obtaining and 
maintaining licenses to market medicinal products in 
as many countries as is necessary. According to the 
present laws all organizations involved in the 
development and marketing of medicinal products 
are legally required to have some form of regulatory 
support.[6] Every country has its own regulatory 
authority, which is responsible to enforce the rules 
and regulations and issue the guidelines to regulate 
the marketing of the drugs.[7] The pharmaceutical 
industry is one of the highly regulated industries, 
with many rules and regulations enforced by the 
government to protect the health and wellbeing of the 
public.[8] There are few differences in the dossier 
submission requirements for among these five 
regions i.e. United State, European Union, India, 
Japan and Canada.[9]Thus a common format of  
 
submission will help in overcoming these challenges. 
Through the international conference on 
harmonization (ICH) process, common technical 
documents (CTD) for United State, European Union, 
India, Japan and Canada.[10]  
 
INTRODUCTION TO GENERIC DRUG 
A generic drug is identical or equivalent to a brand 
drug in dosage form, safety, strength, route of 
administration, quality, performance characteristics 
and intended use. Although generic drug are 
chemically identical to their branded counterparts, 
they are typically sold at substantial discount from 
the branded price. 
Drug Company must submit an Abbreviated New 
Drug Application (ANDA) for approval to market a 
generic product. The drug price competition and 
patent restoration act of 1984 more commonly known 
as Hatch –Waxman Act (HWA), made ANDA 
possible by creating a compromise in drug industry. 
New drug’s products are developed under patent 
protection. The patent protects the investment in the 
drug development by giving the company the sole of 
right to sell the drug while the patent is in effect. 
While the patent and other period of exclusively 
expire, manufacture s can apply to the FDA to sell 
generic version. The ANDA process does not require 
the drug sponsor to repeat costly animal and clinical 
research on ingredients or dosage forms are already 
are approved for safety and effectiveness. 
 Health professionals and consumers can be assured 
the FDA approved generic drug met the same rigid 
standard as the innovator drug.  FDA approval, a 
generic drug must: 
 Be identical in strength, dosage form, and 
route of administration.                                  
 Have same use indication. 
 Be containing the same active ingredient 
as the innovator drug. 
 Bioequivalent 
 Meet the same batch requirement for 
identity, strength, purity and quality  
 Be manufactured under the same strict 
standards of FDA’S good practice 
regulation for   innovator product.[11] 
 
UNITED STATES 
Drug approval standards in the United States are 
considered the most demanding in the world.  The all 
new drugs must first be shown to be safe and 
effective before they can be approved by the Food  
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and Drug Administration (FDA) for marketing 
Discovering a new drug, FDA review process, can 
take many years, and cost hundreds of millions of 
dollars.  To a large degree, these costs are mostly 
associated with the clinical testing that must be done 
to convince the agency that the new product is safe 
and effective for its intended medical use. To begin 
clinical testing, drug companies or sponsors must file 
an Investigational New Drug (IND) application with 
the FDA. The INDs must include information about 
the study protocol, the qualifications of the lead 
investigator, the trial’s location, and assurance that 
the welfare of the study participants will be protected. 
Once new drug’s clinical testing is complete, the 
sponsor submits a New Drug Application (NDA) for 
FDA evaluation. During the application’s review, 
agency officials examine the drug’s safety and 
efficacy data, assay samples, and conduct factory 
inspections to be sure the finished product will be 
manufactured properly . FDA also checks the drug’s 
labeling to be sure that it is accurate and 
comprehensive. Once a new drug is approved, its 
safety is monitored  through FDA’s post-marketing 
surveillance.[12] Abbreviated New Drug 
Application( ANDA) contains data which when 
submitted to FDA Center for Drug Evaluation and 
Research, office of generic drug provides for the 
approval of a generic drug product. The legislation 
was created to balance the world of generic and brand 
drug industries. It provided accessibility to the 
cheaper generic drugs while still encouraging 
innovation and development of new drugs. The 
generic drug companies were allowed to market the 
drug after the patent and certain exclusivities expired. 
Hatch-Waxman amendment of the federal food, drug 
and cosmetics act established the process by which, 
would be marketers of generic drugs can file 
Abbreviated New Drug Application (ANDA) to seek 
FDA approval of generic drugs. Paragraph IV of the 
act, allows 180 day exclusivity to companies that are 
the "first-to-file" an ANDA against holders 
of patents for branded counterparts. In simple 
words “Hatch-Waxman act is the amendment to 
Federal, Food, Drug and Cosmetics act which 
established the modern system of approval of 
generics.[13] 
 
Types of Applications 
1. Investigational New Drug (IND) 
2. New Drug Application (NDA) 
3. Abbreviated New Drug Application (ANDA) 
4. Biologic License Application (BLA)[14]  
Abbreviated New Drug Application review 
process 
 An applicant  who su`bmits an abbreviated new drug 
application (ANDA) to obtain FDA approval to 
market generic drug product and any person who 
owns an approved application or abbreviated 
application. Abbreviated new drug applications under 
21 CFR subpart 314.94, and amendments, 
supplements, and resubmissions; the items sent by 
parcel post or overnight courier service to the Office 
of Generic Drugs, should be directed to: 
Office of Generic Drugs (HFD-600) 
Center for Drug Evaluation and Research 
Food and Drug Administration 
Metro Park North II, Room 150 
7500 Standish Place 
Rockville, MD 20855 
 
Abbreviated New Drug Application 
A generic drug product is one that is comparable to 
an innovator drug product (also known as the 
reference listed drug (RLD) product as identified in 
the FDA's list of Approved Drug Products with 
Therapeutic Equivalence Evaluations (orange 
book)in dosage form, strength, route of 
administration, quality, performance characteristics 
and intended use. Once approved an applicant may 
manufacture and market the generic drug product 
provided all patent protection and exclusivity 
associated with the RLD have expired. Generic drug 
applications are termed "abbreviated" in that they are 
not required to provide clinical data to establish 
safety and efficacy, since these parameters have 
already been established by the approval of the 
innovator drug product (first approved version of the 
drug product marketed under a brand name.[15] 
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Fig1: ANDA review process 
General provision of hatch Waxman act 
The Drug Price Competition and Patent Term 
Restoration Act of 1984 (Pub. L. No. 98-417) (the 
Hatch-Waxman Amendments) amended the Federal 
Food, Drug, and Cosmetic Act (the Act). The Hatch-
Waxman Amendments created section 505(j) of the 
Act (21 U.S.C. 355(j)). Section 505(j) established the 
abbreviated new drug application (ANDA) approval 
process, which allows lower-priced generic versions 
of previously approved innovator drugs to be 
approved and brought on the market. Innovator drug 
applicants must include in a new drug application 
(NDA) information about patents that claim the drug 
product that is the subject of the NDA. FDA 
publishes this patent information as part of the 
Approved Drug Products with Therapeutic 
Equivalence Evaluations, which is generally known 
as the Orange Book. 
An ANDA applicant must include in the ANDA a 
patent certification described in section 
505(j)(2)(A)(vii) of the Act. The certification must 
make one of the following statements:  
 Para1)  no patent information on the drug 
product that is the subject of the ANDA has 
been   submitted to FDA;  
 Para II)  that such patent has expired;  
 Para III)  the date on which such patent 
expires; or  
 Para IV)  that such patent is invalid or will not 
be infringed by the[16]  
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Fig 2: Hatch Waxman amendment 
 
Table1:  Comparison between NDA and ANDA 
 
NDA Requirement ANDA Requirement 
1. Labeling 
2. Pharmacology/toxicology 
3. Chemistry 
4. Manufacturing  
5. Controls 
6. Microbiology 
7. Inspection 
8. Testing 
9. Animal studies 
    10. Clinical studies     
    11.  Bioavailability 
1. Labeling 
2. Pharmacology/toxicology 
3. Chemistry 
4. Manufacturing 
5. Controls 
6. Microbiology 
7. Inspection 
8. Testing 
     
              9.   Bioequivalence 
 
 HATCH WAXMAN AMENMENTS BENIFITS 
TO INOVATOR’S COMPANIES 
TO GENERIC DRUG COMPANIES 
IF SUIT 
180 DAY EXCLUSIVITY PERIOD 
TO CHALLEGE PATENT DRUG  
45 DAY TO CLAIM 
DELAYED FOR 30 MONTHS 
NOT SUIT 
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EUROPE 
The European Union (EU), consisting of 27 Member 
States, has continuously worked on improving and 
streamlining drug review and marketing authorization 
processes. There are currently three different 
procedures that can be used to submit a medicinal 
product for marketing approval in the European 
Union.  
These three procedures are published by the 
European Commission in consultation with the 
competent authorities of the Member States, the 
European Medicines Agency (EMEA), and interested 
parties. The three procedures that are: 
1. Mutual Recognition Procedure (MRP) 
2. Decentralized Procedure (DCP) 
3.   Centralized Procedure (CP) [17]  
The European Medicines Agency is responsible for 
the scientific evaluation of applications for 
centralized marketing authorizations. Once granted 
by the European Commission, the centralized 
marketing authorization is valid in all EU and EEA- 
EFTA states (Iceland, Liechtenstein and Norway). 
This allows the marketing authorization holder to 
market the medicine and make it available to patients 
and healthcare professionals throughout the EEA.[18] 
According to Article 10(1) of Directive 2001/83/EC a 
generic application can also be submitted in a 
Member State where the reference medicinal product 
has never been authorized.  
Directive 2001/83/EC defines a generic medicinal 
product in Article 10(2) (b) as a medicinal product 
which has: 
 The same qualitative and quantitative 
composition in active substances as the 
reference product. 
 The same pharmaceutical form as the 
reference medicinal product. 
 And whose bioequivalence with the reference 
medicinal product has been demonstrated by 
appropriate bioavailability studies.[19] 
Table 3: Marketing authorization procedure in EU 
Regulatory agencies  Procedure  Function of regulatory agencies 
EMA Centralized procedure Applications for the centralized procedure are made 
directly to the European Medicines Agency (EMA) and 
lead to the granting of a European marketing authorization 
by the Commission which is binding in all Member States. 
Reference member 
state 
Decentralized procedure(DCP) Through this procedure an application for the marketing 
authorization of a medicinal product is submitted 
simultaneously in several Member States, one of them 
being chosen as the "Reference Member State". At the end 
of the procedure national marketing authorizations are 
granted in the reference and in the concerned Member 
States. 
Reference member 
state 
Mutual recognition procedure(MRP) The mutual recognition procedure, which is applicable to 
the majority of conventional medicinal products, is based 
on the principle of recognition of an already existing 
national marketing authorization by one or more Member 
States. 
Member state National procedure National authorizations are still available for medicinal 
products to be marketed in one Member State only. 
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INDIA 
Drugs are regulated in India both central and state 
level through the CDSCO (Central drugs standard 
control organization) under the ministry of health and 
family welfare are responsible for approval new 
drugs, clinical trials and licensing of drugs. Drug 
regulatory authorities issue the licenses at the state 
level. The regulation of drugs, medical devices and 
biological products in India is distributed with in 
various ministries.[20] 
There are mainly two regulatory bodies which 
regulate the drug approval, marketing, production, 
quality and drug price in India. 
CDSCO (The Central Drug Standards and 
Control Organization) 
Ministry of Health and Family Welfare control the 
function of CDSCO  
CDSCO evaluate the standards and measures for 
ensuring the safety, efficacy, and quality of drugs and 
cosmetics. 
CDSCO also regulates the market authorization of 
new drugs and standards of clinical trials. 
 
 
 
CDSCO controls drug imports and approves licenses 
to manufacture the above-mentioned products. 
NPPA (The National Pharmaceutical Pricing 
Authority) 
Department of Chemicals and Petrochemicals control 
the function of NPPA. 
 NPPA fixes or revises the price of bulk drugs and 
formulations. 
NNPA updates the list under price control through 
inclusion and exclusion of drugs in line with 
prescribed guidelines. 
NPPA also maintains data on production, exports and 
imports and market share of pharmaceutical firms. 
NPPA monitors the shortage of medicines in addition 
to providing inputs to Parliament in issues pertaining 
to drug pricing. [21]  
                         
 
Fig 3: Generic drug approval process in INDIA [12] 
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1. Generic drug require Form 44 for approval in 
India. 
 2.A treasury challan  of INR 15,000 is required all 
the active ingredients for more than one year and INR 
50,000 of the active ingredients is approved for less 
than one year in India. 
3. Manufacturing of bulk drugs and raw materials the 
applicant has a manufacturing license for bulk drugs, 
a copy of the same is needs to be submitted.  
4. Chemical and pharmaceutical information 
including:  
Information on active ingredients  
a) Brief Chemical & pharmaceutical data on 
Formulation  
a) Master manufacturing formula  
b) Details of the formulation (including inactive 
ingredients)  
c) Finished product specification  
d) In process quality control check  
e) Certificate of analysis including identification, pH, 
content uniformity, impurities, assay etc.  
f) Comparative Dissolution data in case oral dosage 
form as appropriate  
g) Stability study evaluation as per requirements of 
schedule Y 
5. Regulatory status of the drug including names of 
the company’s marketing the drug in the country 
6. Bioavailability/Bioequivalence study reports (for 
oral dosage forms 
7. In case of injectables formulation, sub-acute 
toxicity data conducted with the applicants’ product 
has to be provided.  
8. Prescribing information  
9. Draft of labels and carton  
10. Copy of License in Form-29[22]  
The Indian generic drug Pharmaceutical Industry is 
the top five producers of bulk drugs in the world. The 
Pharmaceuticals market can be divided into Bulk 
drugs and formulations. The bulk drug acquire 20% 
of the market with growth rates of 20% and 
formulations acquire 80% of the market with an 
annual growth rate of 15%.The Indian generic drug 
market growing rapidly because a lot of patent 
expire, major pharmaceutical companies of the world 
interested to invest in Indian market.[23] 
JAPAN 
Generic drug approval review in Japan is conducted 
by the Office of Generic Drugs.[24] which is part of 
the Pharmaceuticals and Medical Devices Agency 
(PMDA), is responsible for the approval review of 
generic drugs in Japan. The PMDA reviews the 
equivalence of generic and original drugs from the 
viewpoint of quality, efficacy, and safety, based on a 
document submitted by generic drug applicants. 
There are two application types for new generic 
drugs and partial change approval in Japan. New 
generic drug applications are submitted as the first 
application, and partial change applications are 
submitted after for post-approval changes. The 
approval content in Japan includes the indication, 
effects, directions, dose, specifications, test methods, 
storage method, validity period, manufacturing 
method, formulation or manufacturing site, and brand 
name. If the applicant for a generic drug performs 
post-approval change on these contents, with the 
exception of minor changes, the PMDA review is 
necessary for partial change approval. [25] 
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         Fig 4: Generic drug approval process in Japan 
 
       Main Data Required for the Approval of Generic Drugs 
a) The manufacturing methods, standards, and test methods, which are used for evaluations of specifications 
and test methods (and manufacturing methods, in some cases). 
b) Stability data, which is used to conduct accelerated tests. 
c) Absorption, distribution, metabolism, and excretion data, which are used in bioequivalence evaluations. 
[26]  
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Table 4: Data Required for the Approval of Generic Drugs 
 
  
Requirements in Japan ( Data to be submitted with an application for approval) 
 
Originator 
Data required 
 
Generic  
Data 
require 
A) Origin or background of 
discovery of use in foreign country  
1) ) Origin or background of discovery Yes No 
2) Condition of use in foreign country Yes No 
3) Special characteristics, comparisons with other 
drugs etc.  
Yes No 
B) Manufacturing methods, 
standards and test methods 
1) Chemical structure and physiochemical 
properties etc. 
Yes No 
2) Manufacturing methods Yes Case based 
3) Specification and test methods Yes No 
C) Stability  1) Long term storage test Yes No 
2) Test under service conditions Yes No 
3) Accelerated tests Yes No 
D) Pharmacological action  1) Test to support efficacy  Yes No 
2) Secondary pharmacology, safety pharmacology Yes No 
3) Other pharmacology Yes No 
E) Absorption, distribution, 
metabolism and excretion 
1) Absorption Yes No 
2) Distribution Yes No 
3) Metabolism Yes No 
4) Excretion Yes No 
5) Bioequivalence Yes No 
6) Other pharmacokinetics Yes No 
F) Acute sub-acute and chronic 
toxicity, teratogenicity and other 
toxicity 
1) Single dose toxicity Yes No 
2) Repeated dose toxicity Yes No 
3) Genotoxicity Yes No 
4) Carcinogenicity  Yes No 
5) Reproductive toxicity Yes No 
6) Local irritation  Yes No 
7) Other toxicity Yes No 
G) Clinical study  Clinical trial results Yes No 
 
Generic drug market share in Japan  
The share of generics in the prescription drugs 
market has been dramatically increasing in terms of 
both volume and value. The recent volume share was 
60.1% in the 2nd quarter in 2016.[27] 
 
Japanese government introduced an initiative for 
increasing generic usage that aims to increase generic 
share by volume to over 60 percent by the end of 
FY2017 (March 2018). [28]  
 
Japan represents the world’s eighth biggest market 
for generic drugs. The government has also made a 
target towards achieving a generic penetration of 
60% by 2017. This is expected to create huge 
opportunities for both domestic and foreign generic 
manufacturers in Japan. [29] 
 
CANADA 
Generic pharmaceuticals generics play an important 
part in helping to control prescription drug costs in 
Canada. Generics are determined by Health Canada 
to be “bioequivalent” to patented pharmaceuticals. 
Their role is to provide competition for brand name 
products when their patent protection ends. In order 
to market an IG in Canada, a manufacturer must 
obtain approval from Health Canada under the 
Patented Medicines (Notice of Compliance) 
Regulations (NOC Regulations).[30]   
All drugs sold in Canada (including pharmaceuticals, 
natural health products, biological and 
radiopharmaceuticals) – both those manufactured 
domestically and imported, must be authorized for 
sale by Health Canada.  
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New Drug Submissions and Supplementary New 
Drug Submissions (SNDS) 
To gain Health Canada authorization for a new drug, 
a manufacturer, typically an innovator, submits a 
New Drug Submission NDS setting out all data 
(obtained through rigorous clinical testing) 
establishing the safety and efficacy of the drug. Such 
submissions typically require pre-clinical, clinical, 
chemistry and manufacturing data. Health Canada 
then reviews the submitted information and evaluates 
the drug’s safety, efficacy and quality to determine 
whether it is suitable to be marketed in Canada and 
whether a Notice of Compliance should, accordingly, 
be issued. Once a drug has been approved, any 
changes to the approval (e.g., change of name, 
packaging, product monograph) requires the 
manufacturer to file a Supplementary New Drug 
Submission SNDS. Changes requiring the submission 
of a SNDS are those made: 
i. In the identifying name of the drug product 
or the brand name; 
ii.  In the dosage form or strength of the drug 
product; 
iii.  In the formulation, method of manufacture, 
equipment, or process control of the drug 
product that requires supporting clinical or 
bioequivalence data; 
iv.  In the case of Schedule C and D drugs, in 
the production site, method of manufacture, 
equipment and process control of the drug 
substance or in the formulation, method of 
manufacture, equipment, process control or 
production site of the drug product; 
v. In the labeling, including package inserts, 
product brochures, file cards, and product 
monographs of the drug product respecting, 
either explicitly or implicitly: 
a) The recommended route of administration of 
the drug product; 
b) The dosage of the drug product, and 
c) The claims, including indications, made for 
the drug product; or for sterile drug 
products, in the specifications to remove the 
sterility test and replace it with process 
parametric release.  
Abbreviated New Drug Submissions (ANDS) 
Where a second or subsequent manufacturer, 
typically a generic manufacturer, seeks a Notice of 
Compliance on the basis of a direct or indirect 
comparison between its drug and the original 
innovative drug which has already received 
marketing approval (called the “Canadian Reference 
Product”), the generic manufacturer submits an 
Abbreviated New Drug Submission (ANDS) 
demonstrating that the generic formulation of the 
drug is bioequivalent to the brand formulation. The 
ANDS typically does not contain clinical data. By 
establishing bioequivalence, a generic manufacturer 
may demonstrate the safety and effectiveness of its 
drug by comparison, without having to complete 
costly and time-consuming clinical trials.[31] 
Comparison of generic drug filling in different 
countries 
worldwide Food and Drug Administration (FDA) in 
United States, European Medicine Agency (EU) in 
Europe, Central Drug Standard Control Organization 
(CDSO) in India,  Ministry of Health Labor The 
regulatory requirements and filling procedure of drug 
product of  different countries in the world are 
different from each other. The role of these 
regulatory authorities is to ensure the quality, safety, 
and efficacy of all medicines in their country. The 
pharmaceutical industry is one of the highly regulated 
with many rule and regulation enforcement by the 
government to protect public health.  It is the 
responsibility of the national government to establish 
regulatory with strong guidelines for quality 
assurance and drug regulation in the different 
territories. The aim of the pharmaceutical industry is 
to identify and develop a generic drug product. To 
make a generic drug product formulator, must know 
the details of the exact regulatory requirements and 
filling procedure of each concerned countries. 
Generic drug development uses a different approach 
and strategy compared to that used to develop a 
innovator drug product. Generic drug manufactures 
must formulate a drug product that will have the 
same therapeutic, safety and performance 
characteristics as of brand name product. Different 
regulatory authorities which are use as and Welfare 
(MHLW), Health Product and Food Branch (HPFB) 
in Canada, Medicines and Healthcare Products 
Regulatory Agency (MHRA) In UK,  Therapeutic 
Good  Administration (TGA) in Australia. 
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Comparison Table 5: 
Sr No. REQUIREMENT US EU INDIA JAPAN CANADA 
A.  ADMINISTRATTION 
1 
Regulatory 
Authority 
Food and drug 
Administration 
European 
medicine 
agency 
Central drug 
standard and 
control 
organization 
Ministry of health 
labor and welfare 
HEALH 
PRODUCT 
AND FOOD 
BRANCH 
2 Application ANDA MAA MAA PDMA ANDS 
3 Debarment certification Required NA NA NA NA 
4 No. of copies 
3(archival, 
review, field) 
1 1 Not specified 3 
5 Approval time line 18 month 12 month 12 month 12 MONTHS 
12-18 
MONTH 
6 Clinical studies Fees  10-20 lakh 50000 Rs. 654200 yen 10000$ 
7 Presentation eCTD  & paper 
eCTD, 
paper along 
with NeeS 
paper 
 
ectd 
eCTD 
8 Pharmacovigilance Not required Required Required Required Required 
9 Agent authorization Required Not required Not required Not required 
NOT 
REQUIRED 
B.  FINISHED PRODUCT CONTROL 
1 Assay 90-100% 95-105% 90-110% 90-111% 90-110% 
2 Disintegration Not required Required Required Required Required 
3 Colour identification Not required Required Required Required Required 
4 Water content Required Not required Required Required 
Required 
when 
material 
hygroscopic 
C. MANUFACTURING AND CONTROL 
1 No. of batches 1 3 1 1 3 
2 Packaging 
A 
minimum  
of 100000 
unit 
Not required 
Not such 
required 
Not such required 
100000 
UNIT 
3 Process validation 
Not 
required at 
the time of 
submission 
Required Required Required Required 
D. LABELING REQUIREMENT 
1 Prescription status Rx POM Rx RX Rx 
2 Labels 
Vials/carto
n/PIL 
Vials/carton/P
IL 
Proposed 
Draft labels 
And cartoons 
Provided in 
Module 1 
VIALS, 
AMPOULES,INJECT
IONS 
blister pack, 
bottle, cover, 
sachet, strip 
pack, tube, 
vessel, vial 
3 Side by side comparison 
REQUIRE
D 
Required REQUIRED NOT SPECIFIED 
 
 
 
 
Required 
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E. STABILITY 
1 
Date and time of 
submission 
3 months 
accelerate 
and 3 
months 
long term 
6 months 
accelerate and 
6 months long 
term 
6 months 
accelerate and 3 
months long 
term 
6 month accelerated 
12 month 
accelerate 
and 3 months 
long term 
2 Container orientation 
Inverted 
upright 
Do not 
address 
Do not address Don not address 
Container 
closer system 
3 QP certification 
Not 
required 
Required Required Required Required 
5 Retention of sample 
5 years 
from the 
date of 
filing the 
application 
No such 
required but 
usually 
followed 
3 years from the 
date of filing the 
application 
Not such required 
 
 
Not such 
required 
 
SUMMARY AND CONCLUSION 
Generic drug manufacturing is a major part of the 
pharmaceutical industry and grow rapidly because to 
the patent expire of the branded drugs. The strategy 
of encouraging generic drug production is important 
at a global level to reduce healthcare costs and to 
enhance drug availability to patients. Generic 
manufacturers may file an abbreviated New Drug 
Application (ANDA) that incorporates the 
safety/effectiveness data submitted by original 
innovator drug manufacturer and adds only 
bioequivalence studies. Paragraph IV provides a 
mechanism for the litigation of patent infringement 
disputes. Hatch-Waxman Act has generally achieved 
the dual goal availability of cheap drugs to consumer 
and providing incentives to innovator pharmaceutical 
drug manufacturers to continue producing innovative 
drugs. Hatch-Waxman established a regulatory 
framework to balance, to entry of generic drugs by 
providing incentives to brand name companies. 
 
In the present study, an attempt was made to search 
the current status of generic drug in global market 
and their regulatory environment. I have studied five 
different countries US, Europe, Japan India and 
Canada although there is a continuous process of 
harmonization. 
 
It is concluded that United Sates have the toughest 
drug approval standard in the world. To sold a new a  
 
drug the pharma manufacturer have to give the proof 
of safety and effectiveness of drug required by the 
law. 
 
In EU pharmaceutical industries follow three 
approval procedures Centralize, Decentralize and 
Mutual Recognition Procedure. For the approval of 
generic drug product Decentralize Procedure is 
followed and in case of new drug approval 
application of marketing authorization is always 
submitted through centralize procedure. The EMEA 
is getting global attention and become gold standard 
in global pharmaceutical. 
 
The Central Drugs Standard Control Organization 
(CDSCO) is the major medical regulatory 
organization in India. Now a day the generic 
pharmaceutical market is an attractive market for 
Indian pharmaceutical companies due to highly 
qualified pool of chemist and low-cost environment. 
It is studied that the condition for approval of generic 
drug is not so easy than EU and US. 
 
In Japan the approval process for generic drug is 
modernizing and government of Japan has ambitious 
goal for improvement of generic drug. Japan has the 
world largest medical market and this country is the 
major target for foreign innovator companies. 
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Canada has one of the world’s largest pharmaceutical 
market. Although it has a share of only 3% in the 
global market. Canadian pharmaceutical market and 
the four elements making it unique including (i) the 
historical compulsory licensing regime (ii) the 
division of customers by federal, provincial and 
territorial drug plants, (iii) the influence of two to 
three large pharmaceutical chains with limited 
advertising due to self-imposed restrictions and (iv) 
the principal agent problem. 
 
It was studied that most regulated authorities are 
similar but a small degree of different requirement 
for the approval of dosage form. It is also concluded 
that similar studies may be performed repeatedly to 
fulfill regulatory environment in different regions of 
the world. The need of standardize regulatory 
requirement has been approved by both regulatory 
authorities and pharmaceutical industry. 
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